"I don't want to manage it, I want to get rid of it" : a narrative analysis of living with chronic plaque psoriasis, and an investigation into vitamin D as a treatment : a thesis presented in partial fulfilment of the requirements for the degree of Doctor of Philosophy in Nutritional Science at Massey University, Albany, New Zealand by Ingram, Michelle Anne
Copyright is owned by the Author of the thesis.  Permission is given for 
a copy to be downloaded by an individual for the purpose of research and 
private study only.  The thesis may not be reproduced elsewhere without 
the permission of the Author. 
 
  
 
 
“I don’t want to manage it, I want to get rid of it”: 
A narrative analysis of living with chronic plaque psoriasis, 
and an investigation into vitamin D as a treatment 
 
 
A thesis presented in partial fulfilment of the requirements for the degree of 
 
Doctor of Philosophy 
in 
Nutritional Science 
 
at Massey University, Albany, New Zealand. 
 
 
 
Michelle Anne Ingram 
2017 
  
 
 
 
 
 
 
 
 
  
 
  
 
i 
Abstract 
As a chronic skin disease, plaque psoriasis can cause significant psychosocial, emotional and 
physical burden.  Psoriasis sufferers perceive others as lacking understanding around what it is 
like to live with this condition, and there has been little research exploring the experience of 
psoriasis in depth.  The burden of psoriasis can be compounded by the difficulty of treating it, 
and the inconveniences, side effects and risks of available treatments, suggesting the importance 
of finding a safe, effective and convenient treatment for psoriasis.  Vitamin D and psoriasis 
have a long-standing relationship, with topical vitamin D analogues used to treat mild-to-
moderate disease, and observational studies suggesting an association between higher systemic 
vitamin D (serum calcidiol) concentrations and less severe psoriasis.  These findings suggest 
vitamin D3 supplements, which raise serum calcidiol concentrations, might improve psoriasis.  
In this thesis, two studies were conducted to address the limited in-depth understanding of the 
experience of psoriasis, and the need for a safe, effective treatment, respectively.  The aims 
were 1) to gain a deeper understanding of the experience of living with psoriasis; and 2) to 
investigate whether oral vitamin D3 supplements can effectively treat psoriasis.   
For 1), data from semi-structured interviews with 10 men and women with psoriasis was 
analysed using narrative analysis.  Narrative trajectories involving three predominant narrative 
forms shaped participants’ stories: restitution, where the focus was on overcoming psoriasis 
through trying to find an effective treatment or cure; chaos, where psoriasis was experienced as 
overwhelming and brought about a sense of hopelessness, and resignation, which was centred 
on begrudgingly accepting psoriasis in order to be able to get on with life.  Participants had 
different narrative trajectories and shifted between forms over time, with the nature of 
experience linked with the relative stability and severity of a person’s psoriasis and their beliefs 
about their ability to manage it.  
For 2), a randomised, double-blinded, placebo-controlled trial was conducted with 101 
participants ≥ 18 years allocated to 100,000 International Units (IU) vitamin D3/month (n = 67) 
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for 12 months (200,000 IU at baseline), or an identical placebo (n = 34).  Psoriasis severity 
(Psoriasis Area and Severity Index [PASI]) and serum calcidiol concentrations were assessed at 
3-monthly intervals. The primary outcome was the difference in PASI between treatment and 
placebo over time, assessed using a linear mixed model.  Psoriasis severity did not differ 
between groups at any time (group F(1, 106) = 0.59, p = 0.44, group*time F(4, 370) = 0.52, p = 
0.72).  Yet these findings are inconclusive, as serum calcidiol significantly increased from 
baseline in both the treatment and the placebo group, and a mild improvement in PASI score 
from baseline also occurred in each group.  A non-predetermined secondary analysis was 
performed by assessing the strength of the relationship between serum calcidiol concentration 
and PASI score across the whole sample, and this showed a significant inverse relationship 
between the two variables, in that elevation of serum calcidiol concentration by increments from 
25 nmol/L to 125 nmol/L was associated with very mild decreases in PASI (estimated range of 
decrease 0 – 2.6; p = 0.002).  Therefore, despite being unable to determine a benefit of vitamin 
D3 supplements for psoriasis, these findings support the notion of a potential benefit of 
increasing serum calcidiol concentrations across the psoriatic population.       
In conclusion, this thesis offers insight into ways in which people can experience psoriasis over 
time: as a temporary and fixable condition that must be overcome, as an overpowering force and 
source of significant suffering, and as a permanent condition that is reluctantly accepted.  As the 
findings emphasise the negative influence of the difficulties around managing and treating 
psoriasis on the experience of psoriasis, they provide further support for the need for an 
effective, safe and convenient treatment. While the findings were inconclusive in regards to 
whether oral vitamin D3 can help people to manage their psoriasis, the significant association 
between psoriasis severity and systemic vitamin D concentration supports continued research 
into this potential. 
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I was engaged in a relentless physical assault on my symptoms, at war with my skin . . . and 
inevitably losing. The disease and its treatment merged, combining inextricably to impact upon 
my personal experience and social identity; a sad fact that both were in effect demeaning….  If 
my self-esteem was affected by the disease, the treatment made the damage worse  
(Jobling, 2007, pp. 953-4). 
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Preface 
The origins of this thesis began in an interest in vitamin D, and the subsequent decision to 
conduct a randomised controlled trial investigating whether vitamin D could effectively treat 
psoriasis.  I had also intended to assess participants’ quality of life and the extent they suffered 
from physical disability because of their psoriasis, and I was going to do so by using 
quantitative questionnaires over the five times I met with each participant over their year of 
enrolment in the trial.  Yet, once I began to meet with participants, out came telling anecdotes, 
outlooks on life, conversational snippets that alluded to formative experiences but never quite 
explained them.  I sensed that some participants lived in the throes of the burden of psoriasis, 
while those who did not had left the weight of their concerns somewhere in the past.  Psoriasis 
seemed much more than a disease of the skin, of the body; it appeared to have shaped the lives 
of many of my participants through impacting their self-perception and experiences.  I also 
suspected that the comments that were shared did not usually reach the open, yet here, in the 
privacy of the researcher/participant relationship, they were inching their way to the surface.  I 
reflected on my research project: in the hands of Likert-scaled questionnaires, these stories 
would disappear amongst the coding.  I wanted to hear more, to look deeper, and in some sense, 
to provide an anonymous voice for these experiences.  I wanted to know how having psoriasis 
affects a person’s life through impacting the experiences that they navigate over time, each 
inevitably leaving its mark somehow etched in the present day.  I was also aware that available 
psoriasis treatments are not always effective, can be inconvenient, and have risks and side 
effects, and therefore can compound the reduced quality of life that is frequently seen in people 
with psoriasis.  I wondered, what are the implications of the drawbacks of treatments on a 
personal level?  Why is it so important that I investigate the potential of vitamin D (which is 
safe, easily administered and has no side effects) as a treatment for psoriasis?  And thus, my 
thesis metamorphosed, from a story based around serum vitamin D concentrations and 
somewhat objective skin assessments, to include a story about people, their experiences of 
living with psoriasis and their search for effective treatments, all of this adding meaning to my 
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investigation into the treatment potential of vitamin D.  This thesis is therefore comprised of 
two complementary parts, each aligning with one of the overall aims as set out below.  In order 
to conduct both parts of this research it has been necessary to take an inter-disciplinary approach 
to this thesis, using narrative theory and analysis based on qualitative research traditions 
alongside quantitative methods.  My hope is that this approach provides a deeper, richer 
understanding of the impact of psoriasis on people’s lives, and illustrates why it is so important 
to find a treatment for psoriasis that is free of risks and side effects. 
 
Aims of Thesis 
This thesis has two distinct aims, which are approached as two separate research studies.  The 
specific aims of each study are as follows: 
Study One: To gain a deeper understanding of how people experience living with psoriasis 
through identifying and analysing the narratives they use to describe their experiences.   
Study Two: To determine whether oral vitamin D3 supplementation is an effective treatment for 
psoriasis.   
This thesis is presented over seven chapters.  Chapter 1 introduces the thesis as a whole, 
presents a rationale for each study and demonstrates how these studies have complementary 
aims that fit together as part of one thesis.  Chapter 2 provides an overview of psoriasis in order 
to provide context for the aims of this thesis.  This overview discusses the characteristics of 
psoriasis (both clinical and at a cellular level), the numerous co-morbidities it has been 
associated with, and the limited body of knowledge relating to the causes and triggers of 
psoriasis.  It also includes a discussion of the treatments that are currently available for psoriasis 
and their advantages and disadvantages. 
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Chapter 3 presents the background, theoretical and methodological approaches, and the methods 
of Study One: A narrative analysis of living with psoriasis.  It opens with a critical discussion of 
the literature as it pertains to the experience of living with psoriasis, to provide an understanding 
of the broad range of issues that relate to living with psoriasis and thereby providing the 
background for the present study.  This is followed by a presentation of the epistemological and 
methodological approaches for this research, including a critical discussion of the approaches 
taken in previous studies about the experience of psoriasis in order to justify the need for a 
narrative approach.  This chapter concludes with a description of the methods used in the 
present study, including the process that was followed to conduct the narrative analysis.  
Chapter 4 presents the findings of Study One, followed by a discussion of these findings in the 
context of the wider literature. 
Chapter 5 presents the background, methodological approach and methods used in Study Two: 
An investigation into the potential of oral vitamin D3 supplementation as a treatment for 
psoriasis.  It begins with an overview of vitamin D, including its various functions, sources and 
an in-depth discussion of required levels and intakes.  This is followed by a critical discussion 
of the literature regarding the relationship between psoriasis and vitamin D, arguing for the need 
to investigate the potential for vitamin D3 supplements for the treatment of psoriasis.  This is 
followed by a description of the methods and procedures used in the trial. 
Chapter 6 presents the findings of Study Two, and a discussion of these findings in relation to 
the wider literature.   
Finally, an overview of the findings of this thesis, a discussion of their implications and the 
original contributions that this thesis offers are presented in Chapter 7. 
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